Clinical Trial Update: Dyslipaemia, Atherosclerosis Risk and Increased hsCRP and Inflammatory and Oxidative Status in the Spanish Population. Database Analysis of Previous Studies Performed in Spain

View source ↗

Summary

A database analysis of prior Spanish studies evaluated dyslipidemia, risk of atherosclerosis, and inflammatory/oxidative biomarkers (hsCRP) in the Spanish popul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Dyslipidemia

Snippet

Sponsor: AstraZeneca | Conditions: Dyslipaemia, Atherosclerosis Risk | Status: COMPLETED